Search research articles
Contact Us
Filters
Showing results (241-250 of 302) with videos related to
Page
of 31
Sort By:
Breast Cancer Research and Treatment
|
March 20, 2016
A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors
Steven A Limentani, Mario Campone, Thierry Dorval, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2009
Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial
Marc Spielmann, Henri Roché, Thierry Delozier, et al.
Clinical Breast Cancer
|
November 26, 2013
Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2
Kathleen I Pritchard, Howard A Burris, Yoshinori Ito, et al.
Breast Cancer Research and Treatment
|
July 7, 2017
A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer
Hope S Rugo, Olivier Trédan, Jungsil Ro, et al.
The Lancet. Oncology
|
November 28, 2017
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
Sara A Hurvitz, Miguel Martin, W Fraser Symmans, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 30, 2009
A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients
Antonin Schmitt, Laurence Gladieff, Amélie Lansiaux, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 6, 2013
Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study
Mario Campone, Thomas Bachelot, Michael Gnant, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 31, 2007
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment
Eva S Thomas, Henry L Gomez, Rubi K Li, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 30, 2018
UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer
Mario Campone, Magali Lacroix-Triki, Lise Roca, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 22, 2019
UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroup
Véronique D'Hondt, Jean-Luc Canon, Lise Roca, et al.
Page
of 31
Search research articles
Search
Showing results (241-250 of 302) with videos related to
Sort By:
Page
of 31
Breast Cancer Research and Treatment
|
March 20, 2016
A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors
Steven A Limentani, Mario Campone, Thierry Dorval, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2009
Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial
Marc Spielmann, Henri Roché, Thierry Delozier, et al.
Clinical Breast Cancer
|
November 26, 2013
Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2
Kathleen I Pritchard, Howard A Burris, Yoshinori Ito, et al.
Breast Cancer Research and Treatment
|
July 7, 2017
A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer
Hope S Rugo, Olivier Trédan, Jungsil Ro, et al.
The Lancet. Oncology
|
November 28, 2017
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
Sara A Hurvitz, Miguel Martin, W Fraser Symmans, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 30, 2009
A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients
Antonin Schmitt, Laurence Gladieff, Amélie Lansiaux, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 6, 2013
Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study
Mario Campone, Thomas Bachelot, Michael Gnant, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 31, 2007
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment
Eva S Thomas, Henry L Gomez, Rubi K Li, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 30, 2018
UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer
Mario Campone, Magali Lacroix-Triki, Lise Roca, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 22, 2019
UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroup
Véronique D'Hondt, Jean-Luc Canon, Lise Roca, et al.
Page
of 31